CHINA 3D BIOPRINTING MARKET FORECAST 2023-2030

The China 3D bioprinting market is expected to project a CAGR of 16.91% during the forecast period, 2023-2030, and is predicted to reach a revenue of $198.83 million by 2030.

In China, several domestic companies, like Medprin Regenerative Medical Technologies Co Ltd, are making fast-paced advancements in 3D bioprinting technology. The company’s core technology is biological 3D printing used for developing products and services, including ligament, blood vessels, artificial skin, and personalized skull & maxillofacial repair systems for precision medicine.

Additionally, China is among the leading countries with the most patents and pending applications in the bioprinting space. For instance, Medprin Regenerative Medical Technologies Co Ltd has over 130 patents in medical 3D printing granted from different regulators in China, Japan, Russia, and the United States.

To know more about this report, request a free sample copy

The China 3D bioprinting market scope includes biomaterial, technology, application, component, and end-user. The technology segment includes laser-assisted bioprinting, inkjet-based bioprinting, syringe/extrusion-based bioprinting, magnetic levitation bioprinting, and other technologies.

Inkjet printing was a text and graphics method. Over time, its modules have been adopted to deposit biomaterials or cells as droplet units through several dispensing forces based on piezoelectric actuators or heating reservoirs. The two different methods used to form ink drops in printing are drop-on-demand (DOD) inkjet printing and continuous inkjet (CIJ) printing. Electromagnetic, piezoelectric, and thermal approaches are used to create DOD. Drop-on-demand (DOD) printers are preferred for most applications, given their ink conservation and precision.

Besides, the inkjet bioprinting system helps create drug delivery systems with low-dose medication, on-demand individualized medications, and poorly soluble pharmacologic agents. In addition, inkjet printing has had successful applications in the biomedical sector.

Laser-assisted bioprinting processes use laser energy to pattern cell-laden bioinks in a three-dimensional spatial arrangement using computer-aided design and manufacturing. Their high resolution and reproducibility make them a viable choice for use in biomedical applications like cell printing.

Using lasers for depositing materials enables a non-contact direct-writing process for 3D printing. The processes have slight variations on the basis of the type of laser source and laser transparent print ribbon. The application of a high-energy pulsed laser causes rapid thermal expansion of this sacrificial layer. This further facilitates the propulsion of a small volume of bio-ink onto the substrate with minimal cell damage.

Furthermore, laser-assisted bioprinting has several unique advantages. It is a non-contact process, thereby offering high post-printing cell viability. Clogging is eliminated since it has a nozzle-free approach. The market vendors are making efforts for innovations for competitive advantage. For instance, Poietis announced receiving the grant of a third patent for their laser-assisted 3D bioprinting method. It implements laser-assisted bioprinting as it facilitates the cells to be positioned in three dimensions with good precision and resolution.

The other technologies include stereolithographic, cell electrospinning, paramagnetic & acoustic, and microfluidic chips. Microfluidic techniques majorly integrate chemical or biological functional units into a chip by manipulating the controllable fluids carrying chemical agents, organisms, cells, or biomolecules. Microfluidics has also enabled the creation of organs/microtissues with accurate configurations, attributed to its flexible manipulation, biocompatibility, and scale integration on a micro/nanoscale.

Some of the leading companies in the China 3D bioprinting market are EnvisionTEC Ṁ Inc, CollPlant Biotechnologies Ltd, Cyfuse Biomedical KK, CELLINK, etc.

Cyfuse Biomedical KK is engaged in the research & development, and commercialization of cell-based products and tissue fabrication systems. It develops & sells 3D biofabrication systems and related consumables and licenses 3D tissue products for drug development and therapeutic use. The company has its headquarters in Tokyo, Japan, and majorly operates in Asia-Pacific.

Report Synopsis

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.